Expanding the Limits of Liver Transplantation for Hepatocellular Carcinoma: Is There a Limit?
Hepatocellular carcinoma
Liver transplantation
Organ allocation
Organ utility
Survival benefit
Survival threshold
Journal
Clinics in liver disease
ISSN: 1557-8224
Titre abrégé: Clin Liver Dis
Pays: United States
ID NLM: 9710002
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
entrez:
12
5
2021
pubmed:
13
5
2021
medline:
26
10
2021
Statut:
ppublish
Résumé
Liver transplantation is a treatment option for hepatocellular carcinoma within Milan criteria. With careful selection practices, patients with larger tumors can do well with successful downstaging followed by liver transplantation and should not be excluded based on tumor size or number alone. When considering expanded criteria for hepatocellular carcinoma, however, survival outcomes after liver transplantation should be comparable with patients without hepatocellular carcinoma. Surrogate measures of tumor biology, such as α-fetoprotein, other biomarkers, and dynamic tumor behavior including response to locoregional therapy can aid in risk stratification of patients before liver transplantation.
Identifiants
pubmed: 33978578
pii: S1089-3261(20)30066-0
doi: 10.1016/j.cld.2020.08.002
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
19-33Subventions
Organisme : NIAID NIH HHS
ID : R25 AI147369
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have nothing to disclose.